Author
Listed:
- Laith J. Abu-Raddad
(Weill Cornell Medicine-Qatar, Cornell University
Cornell University, Qatar Foundation – Education City
Cornell University
Qatar University)
- Hiam Chemaitelly
(Weill Cornell Medicine-Qatar, Cornell University
Cornell University, Qatar Foundation – Education City
Cornell University)
- Houssein H. Ayoub
(Qatar University)
- Patrick Tang
(Sidra Medicine)
- Peter Coyle
(Hamad Medical Corporation
Qatar University
Queens University)
- Mohammad R. Hasan
(Sidra Medicine)
- Hadi M. Yassine
(Qatar University
Qatar University)
- Fatiha M. Benslimane
(Qatar University
Qatar University)
- Hebah A. Al-Khatib
(Qatar University
Qatar University)
- Zaina Al-Kanaani
(Hamad Medical Corporation)
- Einas Al-Kuwari
(Hamad Medical Corporation)
- Andrew Jeremijenko
(Hamad Medical Corporation)
- Anvar Hassan Kaleeckal
(Hamad Medical Corporation)
- Ali Nizar Latif
(Hamad Medical Corporation)
- Riyazuddin Mohammad Shaik
(Hamad Medical Corporation)
- Hanan F. Abdul-Rahim
(Qatar University)
- Gheyath K. Nasrallah
(Qatar University
Qatar University)
- Mohamed Ghaith Al-Kuwari
(Primary Health Care Corporation)
- Adeel A. Butt
(Cornell University
Hamad Medical Corporation)
- Hamad Eid Al-Romaihi
(Ministry of Public Health)
- Abdullatif Al-Khal
(Hamad Medical Corporation)
- Mohametabd H. Al-Thani
(Ministry of Public Health)
- Roberto Bertollini
(Ministry of Public Health)
Abstract
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold (Ct) value is inversely correlated with viral load and culturable virus. Here, we investigate differences in RT-qPCR Ct values across Qatar’s national cohorts of primary infections, reinfections, BNT162b2 (Pfizer-BioNTech) breakthrough infections, and mRNA-1273 (Moderna) breakthrough infections. Our matched-cohort analyses of the randomly diagnosed infections show higher mean Ct value in all cohorts of breakthrough infections compared to the cohort of primary infections in unvaccinated individuals. The Ct value is 1.3 (95% CI: 0.9–1.8) cycles higher for BNT162b2 breakthrough infections, 3.2 (95% CI: 1.9–4.5) cycles higher for mRNA-1273 breakthrough infections, and 4.0 (95% CI: 3.5–4.5) cycles higher for reinfections in unvaccinated individuals. Since Ct value correlates inversely with SARS-CoV-2 infectiousness, these differences imply that vaccine breakthrough infections and reinfections are less infectious than primary infections in unvaccinated individuals. Public health benefits of vaccination may have been underestimated, as COVID-19 vaccines not only protect against acquisition of infection, but also appear to protect against transmission of infection.
Suggested Citation
Laith J. Abu-Raddad & Hiam Chemaitelly & Houssein H. Ayoub & Patrick Tang & Peter Coyle & Mohammad R. Hasan & Hadi M. Yassine & Fatiha M. Benslimane & Hebah A. Al-Khatib & Zaina Al-Kanaani & Einas Al-, 2022.
"Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections,"
Nature Communications, Nature, vol. 13(1), pages 1-11, December.
Handle:
RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28199-7
DOI: 10.1038/s41467-022-28199-7
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28199-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.